solvent-free itraconazole Complex IR

Solvent-free itraconazole Complex IR is a specialized oral immediate-release formulation of the triazole antifungal agent itraconazole, developed by Harvest Moon Pharmaceuticals. Itraconazole exerts its antifungal effect by inhibiting the fungal enzyme lanosterol 14-alpha-demethylase (CYP51), a cytochrome P450-dependent enzyme essential for converting lanosterol to ergosterol. The resulting depletion of ergosterol and accumulation of methylated sterol precursors disrupt fungal cell membrane integrity and function. This specific formulation utilizes a solvent-free complexation approach intended to enhance the bioavailability and solubility of itraconazole, which is traditionally poorly soluble, without the use of organic solvents. It is being developed as a complex generic or improved formulation for the treatment of various fungal infections.

Other names

itraconazole Complex IRsolvent-free itraconazole